Amyloid imaging and memory change for prediction of cognitive impairment

Alzheimer's Research and Therapy

Volumn 3, Issue 1, 2011, Pages

  Resnick, Susan M ^a   Sojkova, Jitka ^a,b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; FLUTEMETAMOL F 18;

ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; HUMAN; IMAGING; IN VIVO STUDY; MEMORY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW;

EID: 82955170032     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt62     Document Type: Review

References (54)

1. Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). RJ O'Brien, SM Resnick, AB Zonderman, L Ferrucci, BJ Crain, O Pletnikova, G Rudow, D Iacono, MA Riudavets, I Driscoll, DL Price, LJ Martin, JC Troncoso, J Alzheimers Dis 2009 18 665 675 19661626
2. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. JL Price, DW McKeel Jr, VD Buckles, CM Roe, C Xiong, M Grundman, LA Hansen, RC Petersen, JE Parisi, DW Dickson, CD Smith, DG Davis, FA Schmitt, WR Markesbery, J Kaye, R Kurlan, C Hulette, BF Kurland, R Higdon, W Kukull, JC Morris, Neurobiol Aging 2009 30 1026 1036 10.1016/j.neurobiolaging. 2009.04.002 19376612
3. Frequent amyloid deposition without significant cognitive impairment among the elderly. HJ Aizenstein, RD Nebes, JA Saxton, JC Price, CA Mathis, ND Tsopelas, SK Ziolko, JA James, BE Snitz, PR Houck, W Bi, AD Cohen, BJ Lopresti, ST DeKosky, EM Halligan, WE Klunk, Arch Neurol 2008 65 1509 1517 10.1001/archneur.65.11.1509 19001171
4. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. WJ Jagust, D Bandy, K Chen, NL Foster, SM Landau, CA Mathis, JC Price, EM Reiman, D Skovronsky, RA Koeppe, Alzheimers Dement 2010 6 221 229 10.1016/j.jalz.2010.03.003 20451870
5. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. MA Mintun, GN Larossa, YI Sheline, CS Dence, SY Lee, RH Mach, WE Klunk, CA Mathis, ST DeKosky, JC Morris, Neurology 2006 67 446 452 10.1212/01.wnl.0000228230.26044.a4 16894106 (Pubitemid 44214969)
6. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. SM Resnick, J Sojkova, Y Zhou, Y An, W Ye, DP Holt, RF Dannals, CA Mathis, WE Klunk, L Ferrucci, MA Kraut, DF Wong, Neurology 2010 74 807 815 10.1212/WNL.0b013e3181d3e3e9 20147655
7. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. CC Rowe, KA Ellis, M Rimajova, P Bourgeat, KE Pike, G Jones, J Fripp, H Tochon-Danguy, L Morandeau, G O'Keefe, R Price, P Raniga, P Robins, O Acosta, N Lenzo, C Szoeke, O Salvado, R Head, R Martins, CL Masters, D Ames, VL Villemagne, Neurobiol Aging 2010 31 1275 1283 10.1016/j.neurobiolaging.2010.04.007 20472326
8. The neuropathological diagnosis of Alzheimer's disease: clinical-pathological studies. BT Hyman, Neurobiol Aging 1997 18 4 Suppl 27 32 10.1016/S0197-4580(97)00066-3 9330982 (Pubitemid 27454693)
9. Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease. JC Morris, M Storandt, DW McKeel Jr, EH Rubin, JL Price, EA Grant, L Berg, Neurology 1996 46 707 719 8618671
10. Mild cognitive impairment and preclinical Alzheimer's disease. JC Morris, Geriatrics 2005 Suppl 9 14 16025770 (Pubitemid 40840351)
11. Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. I Driscoll, SM Resnick, JC Troncoso, Y An, R O'Brien, AB Zonderman, Ann Neurol 2006 60 688 695 10.1002/ana.21031 17192929 (Pubitemid 46048486)
12. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. JE Galvin, KK Powlishta, K Wilkins, DW McKeel Jr, C Xiong, E Grant, M Storandt, JC Morris, Arch Neurol 2005 62 758 765 10.1001/archneur.62.5.758 15883263 (Pubitemid 40656091)
13. Mild cognitive impairment as a clinical entity and treatment target. RC Petersen, JC Morris, Arch Neurol 2005 62 1160 1163 discussion 1167 10.1001/archneur.62.7.1160 16009779 (Pubitemid 41043744)
14. In vivo human amyloid imaging. J Sojkova, SM Resnick, Curr Alzheimer Res 2011 21222593
15. Amyloid imaging and (what is normal?) aging. WE Klunk, CA Mathis, Imaging the Aging Brain Oxford, USA: Oxford University Press, Jagust WDE, 2009
16. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. CR Jack Jr, VJ Lowe, SD Weigand, HJ Wiste, ML Senjem, DS Knopman, MM Shiung, JL Gunter, BF Boeve, BJ Kemp, M Weiner, RC Petersen, Alzheimer's Disease Neuroimaging Initiative, Brain 2009 132 1355 1365 10.1093/brain/awp062 19339253
17. (18) F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. R Vandenberghe, K Van Laere, A Ivanoiu, E Salmon, C Bastin, E Triau, S Hasselbalch, I Law, A Andersen, A Korner, L Minthon, G Garraux, N Nelissen, G Bormans, C Buckley, R Owenius, L Thurfjell, G Farrar, DJ Brooks, Ann Neurol 2010 68 319 329 10.1002/ana.22068 20687209
18. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). DF Wong, PB Rosenberg, Y Zhou, A Kumar, V Raymont, HT Ravert, RF Dannals, A Nandi, JR Brasi W Ye, J Hilton, C Lyketsos, HF Kung, AD Joshi, DM Skovronsky, MJ Pontecorvo, J Nucl Med 2010 51 913 920 10.2967/jnumed.109.069088 20501908
19. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. CC Rowe, U Ackerman, W Browne, R Mulligan, KL Pike, G O'Keefe, H Tochon-Danguy, G Chan, SU Berlangieri, G Jones, KL Dickinson-Rowe, HP Kung, W Zhang, MP Kung, D Skovronsky, T Dyrks, G Holl, S Krause, M Friebe, L Lehman, S Lindemann, LM Dinkelborg, CL Masters, VL Villemagne, Lancet Neurol 2008 7 129 135 10.1016/S1474-4422(08)70001-2 18191617
20. PET of brain amyloid and tau in mild cognitive impairment. GW Small, V Kepe, LM Ercoli, P Siddarth, SY Bookheimer, KJ Miller, H Lavretsky, AC Burggren, GM Cole, HV Vinters, PM Thompson, SC Huang, N Satyamurthy, ME Phelps, JR Barrio, N Engl J Med 2006 355 2652 2663 10.1056/NEJMoa054625 17182990 (Pubitemid 44969124)
21. Detection of Alzheimer pathology In vivo using both 11C-PIB and 18F-FDDNP PET. N Tolboom, M Yaqub, WM van der Flier, R Boellaard, G Luurtsema, AD Windhorst, F Barkhof, P Scheltens, AA Lammertsma, BN van Berckel, J Nucl Med 2009 50 191 197 10.2967/jnumed.108.056499 19164243
22. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. J Shin, SY Lee, SJ Kim, SH Kim, SJ Cho, YB Kim, Neuroimage 2010 52 488 496 10.1016/j.neuroimage.2010.04.013 20385246
23. PET imaging of amyloid deposition in patients with mild cognitive impairment. A Forsberg, H Engler, O Almkvist, G Blomquist, G Hagman, A Wall, A Ringheim, B Langstrom, A Nordberg, Neurobiol Aging 2008 29 1456 1465 10.1016/j.neurobiolaging.2007.03.029 17499392
24. Conversion of amyloid positive and negative MCI to AD over 3 years. An 11C-PIB PET study. A Okello, J Koivunen, P Edison, HA Archer, FE Turkheimer, K Någren, R Bullock, Z Walker, A Kennedy, NC Fox, MN Rossor, JO Rinne, DJ Brooks, Neurology 2009 73 754 760 10.1212/WNL.0b013e3181b23564 19587325
25. Amyloid imaging in mild cognitive impairment subtypes. DA Wolk, JC Price, JA Saxton, BE Snitz, JA James, OL Lopez, HJ Aizenstein, AD Cohen, LA Weissfeld, CA Mathis, WE Klunk, ST De-Kosky, Ann Neurol 2009 65 557 568 10.1002/ana.21598 19475670
26. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Y Li, JO Rinne, L Mosconi, E Pirraglia, H Rusinek, S DeSanti, N Kemppainen, K Någren, BC Kim, W Tsui, MJ de Leon, Eur J Nucl Med Mol Imaging 2008 35 2169 2181 10.1007/s00259-008- 0833-y 18566819
27. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. JC Price, WE Klunk, BJ Lopresti, X Lu, JA Hoge, SK Ziolko, DP Holt, CC Meltzer, ST DeKosky, CA Mathis, J Cereb Blood Flow Metab 2005 25 1528 1547 10.1038/sj.jcbfm.9600146 15944649 (Pubitemid 41541962)
28. Imaging beta-amyloid burden in aging and dementia. CC Rowe, S Ng, U Ackermann, SJ Gong, K Pike, G Savage, TF Cowie, KL Dickinson, P Maruff, D Darby, C Smith, M Woodward, J Merory, H Tochon-Danguy, G O'Keefe, WE Klunk, CA Mathis, JC Price, CL Masters, VL Villemagne, Neurology 2007 68 1718 1725 10.1212/01.wnl.0000261919.22630.ea 17502554 (Pubitemid 46763260)
29. Comparison of 18F-FDG and PiB PET in cognitive impairment. VJ Lowe, BJ Kemp, CR Jack Jr, M Senjem, S Weigand, M Shiung, G Smith, D Knopman, B Boeve, B Mullan, RC Petersen, J Nucl Med 2009 50 878 886 10.2967/jnumed.108.058529 19443597
30. Deficient high-affinity binding of Pittsburgh compound B in a case of Alzheimer's disease. RF Rosen, BJ Ciliax, TS Wingo, M Gearing, J Dooyema, JJ Lah, JA Ghiso, H Levine, LC Walker, Acta Neuropathol 2010 119 221 233 10.1007/s00401-009-0583-3 19690877
31. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. JC Morris, CM Roe, C Xiong, AM Fagan, AM Goate, DM Holtzman, MA Mintun, Ann Neurol 2010 67 122 131 10.1002/ana.21843 20186853
32. What is cognitive reserve? Theory and research application of the reserve concept. Y Stern, J Int Neuropsychol Soc 2002 8 448 460 10.1017/ S1355617702813248 11939702 (Pubitemid 34296102)
33. Cognition, reserve, and amyloid deposition in normal aging. DM Rentz, JJ Locascio, JA Becker, EK Moran, E Eng, RL Buckner, RA Sperling, KA Johnson, Ann Neurol 2010 67 353 364 10.1001/archneurol.2010.19 20373347
34. Larger temporal volume in elderly with high versus low beta-amyloid deposition. G Chételat, VL Villemagne, KE Pike, JC Baron, P Bourgeat, G Jones, NG Faux, KA Ellis, O Salvado, C Szoeke, RN Martins, D Ames, CL Masters, CC Rowe, Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group, Brain 2010 133 3349 3358 20739349
35. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. KE Pike, G Savage, VL Villemagne, S Ng, SA Moss, P Maruff, CA Mathis, WE Klunk, CL Masters, CC Rowe, Brain 2007 130 2837 2844 10.1093/brain/awm238 17928318 (Pubitemid 350033975)
36. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. N Tolboom, WM van der Flier, M Yaqub, T Koene, R Boellaard, AD Windhorst, P Scheltens, AA Lammertsma, BN van Berckel, Neurology 2009 73 2079 2085 10.1212/WNL.0b013e3181c679cc 20018636
37. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. A Forsberg, O Almkvist, H Engler, A Wall, B Langstrom, A Nordberg, Curr Alzheimer Res 2010 7 56 66 10.2174/156720510790274446 20205671
38. Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. CM Roe, MA Mintun, G D'Angelo, C Xiong, EA Grant, JC Morris, Arch Neurol 2008 65 1467 1471 10.1001/archneur.65.11.1467 19001165
39. Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease. MN Braskie, AD Klunder, KM Hayashi, H Protas, V Kepe, KJ Miller, SC Huang, JR Barrio, LM Ercoli, P Siddarth, N Satyamurthy, J Liu, AW Toga, SY Bookheimer, GW Small, PM Thompson, Neurobiol Aging 2010 31 1669 1678 10.1016/j.neurobiolaging.2008.09.012 19004525
40. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. AJ Furst, GD Rabinovici, AH Rostomian, T Steed, A Alkalay, C Racine, BL Miller, WJ Jagust, Neurobiol Aging 2010 20417582
41. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. EC Mormino, JT Kluth, CM Madison, GD Rabinovici, SL Baker, BL Miller, RA Koeppe, CA Mathis, MW Weiner, WJ Jagust, Brain 2009 132 1310 1323 10.1093/brain/awn320 19042931
42. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. M Storandt, MA Mintun, D Head, JC Morris, Arch Neurol 2009 66 1476 1481 10.1001/archneurol.2009.272 20008651
43. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. VL Villemagne, KE Pike, D Darby, P Maruff, G Savage, S Ng, U Ackermann, TF Cowie, J Currie, SG Chan, G Jones, H Tochon-Danguy, G O'Keefe, CL Masters, CC Rowe, Neuropsychologia 2008 46 1688 1697 10.1016/j.neuropsychologia.2008.02.008 18343463
44. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. J Koivunen, T Pirttilä N Kemppainen, S Aalto, SK Herukka, AM Jauhianen, T Hänninen, M Hallikainen, K Någren, JO Rinne, H Soininen, Dement Geriatr Cogn Disord 2008 26 378 383 10.1159/000163927 18931497
45. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. JC Morris, CM Roe, EA Grant, D Head, M Storandt, AM Goate, AM Fagan, DM Holtzman, MA Mintun, Arch Neurol 2009 66 1469 1475 10.1001/archneurol.2009.269 20008650
46. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. KA Johnson, M Gregas, JA Becker, C Kinnecom, DH Salat, EK Moran, EE Smith, J Rosand, DM Rentz, WE Klunk, CA Mathis, JC Price, ST Dekosky, AJ Fischman, SM Greenberg, Ann Neurol 2007 62 229 234 10.1002/ana.21164 17683091 (Pubitemid 47525398)
47. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. C Davatzikos, F Xu, Y An, Y Fan, SM Resnick, Brain 2009 132 2026 2035 10.1093/brain/awp091 19416949
48. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. JO Rinne, DJ Brooks, MN Rossor, NC Fox, R Bullock, WE Klunk, CA Mathis, K Blennow, J Barakos, AA Okello, Liano S Rodriguez Martinez de, E Liu, M Koller, KM Gregg, D Schenk, R Black, M Grundman, Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881
49. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. CR Jack Jr, DS Knopman, WJ Jagust, LM Shaw, PS Aisen, MW Weiner, RC Petersen, JQ Trojanowski, Lancet Neurol 2010 9 119 128 10.1016/S1474-4422(09) 70299-6 20083042
50. Neuronal hypertrophy in asymptomatic Alzheimer disease. D Iacono, R O'Brien, SM Resnick, AB Zonderman, O Pletnikova, G Rudow, Y An, MJ West, B Crain, JC Troncoso, J Neuropathol Exp Neurol 2008 67 578 589 10.1097/NEN.0b013e3181772794 18520776 (Pubitemid 351787084)
51. Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. MA Riudavets, D Iacono, SM Resnick, R O'Brien, AB Zonderman, LJ Martin, G Rudow, O Pletnikova, JC Troncoso, Neurobiol Aging 2007 28 1484 1492 10.1016/j.neurobiolaging.2007.05.005 17599696 (Pubitemid 47238539)
52. Predictors of progression in the ADNI-MCI cohort. PS Aisen, Alzheimers Dementia 2010 6 63 10.1016/j.jalz.2010.05.180
53. Inverse relation between In vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. AM Fagan, MA Mintun, RH Mach, SY Lee, CS Dence, AR Shah, GN LaRossa, ML Spinner, WE Klunk, CA Mathis, ST DeKosky, JC Morris, DM Holtzman, Ann Neurol 2006 59 512 519 10.1002/ana.20730 16372280 (Pubitemid 43358072)
54. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. T Grimmer, G Henriksen, HJ Wester, H Forstl, WE Klunk, CA Mathis, A Kurz, A Drzezga, Neurobiol Aging 2009 30 1902 1909 10.1016/j.neurobiolaging.2008.01. 016 18346821